Abbott: 3,000 jobs axed as synergies with Solvay are realized

Following the acquisition of Solvay, Abbott Laboratories plans to lay-off 3,000 global workers. The job cuts are part of Abbott's drive to achieve long-term goals and improve efficiencies, while at the same time increasing sales and per-share earnings. The company's broader strategy is to increase access to emerging markets and diversify its products in the hope of increasing industry growth.

Published By Datamonitor

Abbott: 'real-life' data reinforces Humira efficacy

Data presented at the European League Against Rheumatism conference has shown Humira to be safe and effective in an initial trial involving 2,000 rheumatoid arthritis patients. However, Abbott's [ABT] product has its work cut out to beat its major rivals Enbrel and Remicade in a field where competition is set to intensify.

Published By Datamonitor

Abbott/Millennium: genomics partnership advances

Obesity is a serious public health concern, costing over $100 billion a year in the US alone, and MLN4760 will complement Abbott's metabolic disease program well. It is also the first fruit of a strategic alliance to develop drugs based on genomic research. Such alliances will become increasingly important in the industry over the next few years.

Published By Datamonitor

Abbott/Millennium: a strong alliance

Published By Datamonitor

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.

Published By Datamonitor

Abbott wins bidding war for Solvay

Multi-disciplinary healthcare giant Abbott Laboratories has fought off competition from Nycomed to secure the $6.6 billion acquisition of Solvay's pharmaceutical business. The deal is a very timely one for Abbott and will help accelerate the Chicago drugmaker's expansion in emerging markets and provide it with a novel vaccine development platform.

Published By Datamonitor

Abbott Laboratories: new opportunities from strategic split

The restructuring will allow each new business to develop specific strategies tailored to their distinct markets. This is particularly important for the branded pharmaceutical segment, which is forecast to see low growth over the next five years. Datamonitor expects steady growth from the new medical products company and lower risk for stockholders, itself a primary driver behind this event.

Published By Datamonitor

Abbott Laboratories: Kos Pharmaceuticals a wise buy

Abbott has recently made public its definitive tender offer for US cardiovascular specialists Kos Pharmaceuticals, a deal worth $3.7 billion, or $78 per share. The move signifies Abbott's intention to retain its position in the lucrative lipid management market and will give the company access to Kos Pharma's extensive range of clinical development programs.

Published By Datamonitor

Abbott Laboratories: arthritis drugs lift profits

Abbott's two arthritis drugs, Humira and Mobic, have shown strong sales growth in recent months, significantly boosting the company's second-quarter earnings. Continued growth is forecast for Humira, but this is likely to be eroded by generic threats to Mobic and the return of the drug's rights to its developer, Boehringer Ingelheim.

Published By Datamonitor

Abbott Laboratories/Vysis: agreement for cancer tests

Published By Datamonitor